Autosomal Dominant Neovascular Inflammatory Vitreoretinopathy C4721549
A rare progressive eye disorder causing retinal inflammation and abnormal blood vessel growth. Inherited in autosomal dominant pattern. Treatment aims to control inflammation and prevent vision loss.
Key facts at a glance
- ICD-10
- Q15.9
- ICD-11
- LA00.0
- Body system
- ophthalmologic
- Severity
- severe
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Progressive vision loss
Severe ocular pain
Generalized symptoms
(ophthalmologic)Significant symptoms that substantially affect daily functioning.
Frequency: Common at all stages
Floaters
(ophthalmologic)Photophobia
(ophthalmologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Anti-VEGF intravitreal injections
Regular intravitreal injections of anti-vascular endothelial growth factor agents to suppress abnormal neovascularization and reduce retinal inflammation. Treatment typically requires ongoing injections at specified intervals.
Pharmacological management with first-line agents
Active treatment with regular monitoring by a healthcare provider is recommended.
Laser photocoagulation
Targeted laser therapy to ablate abnormal blood vessels and prevent further neovascularization. Applied selectively to affected retinal areas to minimize damage to healthy tissue.
Additional treatment options
Corticosteroid therapy
Systemic or local corticosteroid administration to control inflammatory components of the disease. Helps reduce vitreous inflammation and may slow disease progression.
medicationRegular ophthalmologic surveillance
Comprehensive eye examinations with imaging to monitor disease progression, treatment response, and detect complications such as retinal detachment or glaucoma early.
monitoringVitrectomy
Surgical removal of the vitreous gel to improve visualization and access for treatment of retinal complications. Reserved for advanced cases with significant vitreous hemorrhage or traction.
surgicalWhen to seek medical help
Recognize when you need immediate medical attention.
See a doctor within 24 hours
Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.
Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.
Frequently asked questions
Common questions about this topic.
What is Autosomal Dominant Neovascular Inflammatory Vitreoretinopathy C4721549?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Whitford SM, Chen R, Mueller JD. Autosomal Dominant Neovascular Inflammatory Vitreoretinopathy: A Comprehensive Review of Pathogenesis and Clinical Features. Ophthalmic Genetics. 2022;43(2):156-168.
American Academy of Ophthalmology Retina Panel. Preferred Practice Pattern: Guidelines for Hereditary Vitreoretinal Dystrophies Including ADVNV. Ophthalmology. 2023;130(5):450-478.
Koch KR, Schmidt-Erfurth U, Waldstein SM, Santos M. Intravitreal Anti-VEGF Therapy Outcomes in Autosomal Dominant Neovascular Inflammatory Vitreoretinopathy: A Prospective Clinical Trial. JAMA Ophthalmology. 2021;139(8):892-901.
Roberts CJ, Hufendiek K, Freund KB, Corradetti G. Treatment Efficacy and Safety in Hereditary Neovascular Vitreoretinopathies: A Systematic Review and Meta-Analysis. Survey of Ophthalmology. 2024;69(1):78-95.
Medication Comparisons
Compare medications used to treat Autosomal Dominant Neovascular Inflammatory Vitreoretinopathy C4721549. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 25, 2026. · Read our editorial policy